MedTrace Logo

Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin

NCT05467033 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 424

Last updated 2025-05-08

No results posted yet for this study

Summary

It is a randomized, multicenter, double-blind, placebo controlled, interventional clinical trial that will be conducted in Poland, in about 6 Hospital Nephrology Departments to evaluate the safety and effectiveness of desmopressin on the prevention of bleeding after percutaneous needle kidney biopsy in patients with rare and ultrarare glomerulonephritis.

Conditions

  • Kidney Biopsy

Interventions

DRUG

Desmopressin

desmopressin 0,3ug/kg in 100ml 0,9% NaCl managed as intravenous infusion;

DRUG

intravenous infusion NaCl

0,9% NaCl managed as intravenous infusion

Sponsors & Collaborators

  • Medical University of Bialystok

    lead OTHER

Principal Investigators

  • Alicja Rydzewska-Rosołowska, Assoc.Prof. · Second Department of Nephrology and Hypertension with Dialysis Unit

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05467033 on ClinicalTrials.gov